Background　Temozolomide,　an　alkylating　agent,　is　a　promising　chemotherapeutic　agent　for　treating　glioblastoma.　Although　chemotherapy　with　temozolomide　may　restrain　tumor　growth　for　some　months,　invariable　tumor　recurrence　suggests　that　cancer　stem　cells　maintaining　these　tumors　persist.　Previous　research　has　shown　that　temozolomide　can　inhibit　the　proliferation　of　human　glioblastoma　stem　cells　(GSCs);　however,　no　research　has　focused　on　the　invasion　of　GSCs,　which　is　an　important　factor　for　glioblastoma　recurrence.　Accumulating　evidence　indicates　that　microRNA　(miR)-125b　over-expression　in　GSCs　may　increase　their　invasiveness.